Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Marisol Quintero(Highlight Therapeutics (Spain)), Juana Oramás(Hospital Universitario de Canarias), Luis de la Cruz‐Merino, Vanesa Pons Sanz(Highlight Therapeutics (Spain)), Pilar López Criado(MD Anderson Cancer Center Madrid), Sonia Maciá(Highlight Therapeutics (Spain)), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Henri Montaudié(Hôpital l'Archet), Sofía España(Institut Català d'Ornitologia), Miguel Fernández de Sanmamed Gutiérrez(Universidad de Navarra), Juan Francisco Rodríguez-Moreno(Hospital Universitario HM Sanchinarro), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Alfonso Berrocal(Hospital General Universitario De Valencia), Helena Escuin-Ordinas(University of California, Los Angeles), Stéphane Dalle(Mount Sinai Hospital), J. Charles(Apple (Israel)), Eduardo Castañón(Clinica Universidad de Navarra), Caroline Robert(Centre National de la Recherche Scientifique), Javier Sánchez-López(Highlight Therapeutics (Spain)), María González Cao(Hospital Universitario Dexeus), Pablo Cerezuela‐Fuentes(Hospital Universitario Virgen de la Arrixaca), Brigitte Dréno(Inserm), María Rojas(Highlight Therapeutics (Spain)), Ana Arance(Hospital Clínic de Barcelona)

Cancer Research

July 1, 2021

Cited by 2

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2014|2k

|New England Journal of Medicine|2018|1.8k

Related Papers